Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Washington University School of Medicine
Pediatric Brain Tumor Consortium
Memorial Sloan Kettering Cancer Center
Duke University
University of California, San Francisco
Legacy Health System
Case Comprehensive Cancer Center
Centre Hospitalier Universitaire Vaudois
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
Eli Lilly and Company